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Introduction
Patients with type 1 diabetes mellitus (T1D) are at a 
great risk for developing autoimmune diseases. It is well 
recognized that T1D can be associated with celiac disease
(CD) and autoimmune thyroid disorders (ATD). Recent studies
regarding CD and T1D have indicated that the frequency 
of this association can vary from 1.7% to 16% (1,2). The 
frequency of ATD in patients with T1D is reported to vary
from 3.9% to 40% in different populations (3). On the other
hand, the frequency of ATD in patients with CD varies from
4.1% to 14% (4). Growth, bone metabolism and fertility can
be affected by these autoimmune associations (4). In this
study, the aim was to investigate the prevalence of CD and
ATD in Turkish pediatric patients with T1D and to correlate
the clinical findings and HLA-genotyping results with the
above-mentioned autoimmune disorders. 
Methods 
The study group consisted of 38 children (19 boys, 19
girls) with T1D aged from 1.5 to 16.8 years (mean age;
9.4±2.9 years) who had been followed up in our department
for a mean period of 48.3±28 months.
The diagnosis of T1D was based on clinical findings
(polyuria, polydipsia, polyphagia and weight loss) 
and presence of hyperglycemia (randomised glucose level
≥200 mg/dL). Pancreatic autoantibodies [Islet cell 
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(antiGAD) and anti-insulin autoantibodies (AIA)] were 
also evaluated in all children in the study group (5). In 
addition, HLA-genotyping by polymerase chain reaction 
was  performed in all patients (6). Pancreas-related 
autoantibodies (ICA, anti GAD, AIA) were determined using
radioimmunoassay (RIA) methods (7,8,9).
The immunoglobulin A (IgA) antiendomysium antibody
(EMA) test was selected as the screening test for CD and
performed in all patients. IgA deficiency was excluded in
each patient. Serum samples were analyzed for EMA by the
indirect immunofluorescence method (10). Intestinal biopsy
was performed in patients showing EMA positivity. 
EMA-positive patients with no clinical symptoms suggestive
of CD, but showing typical histopathological findings 
consistent with CD (villous atrophy, elongated crypts, 
infiltration of plasma cells, lymphocytes, eosinophils and
basophils in the lamina propria), were accepted as silent CD
cases, while patients with no clinical symptoms but having
intraepithelial lymphocytosis in the small bowel biopsy were
considered as latent CD cases. Those who exhibited 
gastrointestinal symptoms were categorized as classic CD
patients, and those who had extraintestinal findings-as 
atypical CD patients (11,12). Antibodies for CD and ATD 
were searched for on admission in all patients. Antibody
measurements were rechecked annually. Because variable
nutrient absorption due to CD-associated intestinal injury
may destabilize diabetic control (13), in patients with 
metabolic dysregulation, CD was reinvestigated within a 
period shorter than a year. In patients with CD, after 
gluten-free diet, the metabolic control was evaluated.
Serum free triiodothyronine (T3), free thyroxine (T4), 
thyrotropin (TSH), antithyroglobulin (antiTG), antithyroid 
peroxidase antibody (antiTPO) were measured in all patients.
Serum free T3 and free T4 levels were measured by 
competitive immunoassay method using immunodiagnostic
products  (14). Serum TSH levels were measured 
by immunometric method (15). AntiTG and antiTPO were
measured by immunometric assay, using immulate 2000
(16). Values above 35 U/mL for AntiTg and 40 U/mL for
antiTPO were considered to be positive (16). The thyroid
gland was assessed by palpation and graded according to the
goitre classification system proposed by the World Health
Organization  (17). Thyroid sonography was performed by
high-resolution ultrasound, using 7.5 MHz probes in each
patient. Thyroid volumes were calculated by reference 
criteria  (18). Accordingly, thyroid volumes above 97th
percentile were accepted as goitre (18).
Results 
Somatic growth was within normal limits in all patients.
The clinical and laboratory characteristics of the patients are
shown in Table 1. AIA was the most frequent antibody 
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Table 1. Clinical and laboratory findings of the patients (n=38) (mean±SD or % values given)
Chronologic  Sex BMI Height SDS Duration of  Presence of autoimmune  CD-associated 
age (years) (SDS) T1D (months) markers, n (%)  genotyping, n (%)
Pancreas Thyroid Celiac 
disease
AIA  antiGAD ICA  antiTPO  antiTG EMA      DQ2   DQ8 B8 DR3 DQW2
9.4±2.9 19M         20.6±2.2           -0.4±1.0            37.3±35 27 26        9 11           9 3 11     15     10 6 2
19F (1.1±0.7) (71%)   (26%)   (23%)     (29%)    (23%)    (7.8%)       (29%)  (39%)  (26%)  (15.7%) (5.2%)
Abbreviations given within the text
Table 2. Characteristics of  patients with T1D and CD
Age/ Sex Diagnosis EMA Intestinal biopsy CD type  Symptoms HLA genotype
Patient 1 14/F LADC 3+ CD (IELs) Latent None HLA-B8, DQ2
Short stature
Patient 2 13/F T1D 4+ CD Atypical Hepatosteatosis HLA-B8
Pubertal delay HLA-DQW2
Patient 3 11/F T1D 3+ CD Atypical Metabolic disorders  HLA-DQ8
(uncontrolled diabetes)
EMA: antiendomysium antibody 
LADC: Latent autoimmune diabetes in children
T1D: Type 1 diabetes mellitus
CD: Celiac  disease
IELs: Increased Intraepithelial Lymphocytestype at the time of diagnosis of T1D. AntiTPO and antiTG
antibodies were present in 29% and 23% of patients,
respectively. Twelve of 38 (31.5%) T1D patients were 
positive for one or two antithyroid antibodies. HLA-
genotyping showed that DQ8 was the most frequent type,
followed by DQ2. CD was diagnosed in three children among
these 38 T1D patients (7.8 %). The general characteristics of
cases with T1D and CD are shown in Table 2. In patient 1,
who was diagnosed with latent autoimmune diabetes in 
children (LADC) (19), three of the pancreas-related antibodies
were positive. One patient diagnosed with CD had short
stature, hepatosteatosis and pubertal delay. The third child
had uncontrolled hyperglycemia despite strict insulin and diet
therapy. Patients 1 and 2 diagnosed with CD had also ATD.
Patients with positive results were subjected to a gluten-free
diet, after which, an improvement in the metabolic status
was observed only in the third child.
Discussion 
Autoimmune disorders such as ATD and CD are 
relatively common in diabetic children and serological 
screening studies evaluating the prevalence of CD in patients
with T1D have gained momentum in recent years. Rozsai et
al (10) reported EMA positivity of 6.6% in 196 T1D patients.
Among these, 1.5% were symptomatic CD cases. The 
highest association rate (16.4%) was reported by Barera et al
(20). These authors used antigliadin antibody and EMA tests
as screening methods (21). Cherubini et al (22)
reported EMA positivity in 180 cases with T1D and their 116
healthy male siblings as 6.6% and 5.2%, respectively,
emphasizing the need for serological screening for CD in 
siblings of  T1D patients.
In our study, the association rate for CD  in T1D patients
was 7.8%, a rate which conforms to reported data. One of
these three patients was completely asymptomatic, 
one demonstrated extraintestinal symptoms such as short
stature and pubertal delay, and the third had uncontrolled 
diabetes. 
Investigations have been focused on the effect of 
administering a gluten-free diet based on a diagnosis of CD
on the metabolic control of diabetes (23). A diet initiated upon
determination of CD in a child with T1D and suffering from
malnutrition is expected to lead to weight gain and reduction
in the number of hypoglycemic episodes. A decrease in
hypoglycemic attacks in pediatric cases with T1D associated
with CD after starting a gluten-free diet had been observed
by several investigators (21). However, there are also studies
reporting no change in the incidence of hypoglycemia and
ketoacidosis by gluten-free diet in children with T1D (24). 
We found improvement in the metabolic control in only one
CD patients. 
The DR3/DQ2 tissue type determined in one of our
patients (Table 2) favors the co-existence of LADC and CD
(19). It has been reported that the CD-related antibodies
increase in frequency in the first-degree relatives of T1D
patients  (25). Studies have clearly shown that there is a 
significantly higher incidence of HLA B8, DR3 and DQW2 in
CD. The common genetic background may play a role in the
immune response mechanism (1). Recent studies have
shown that HLADQ polymorphisms (HLA-DQA1 DQB1) 
significantly modify the risk of ATD in children with T1D (3).
In our study, 39% T1D patients had DQ8 and 29% had DQ2
genotypes that are known as risk factors in CD.  
Many patients with T1D are euthyroid at the time of 
diagnosis of ATD. However, overt or subclinical 
hypothyroidism was reported in 17-58 % of diabetic patients
with  positive thyroid autoantibodies (26). In our study, two
cases had subclinical hypothyroidism and ten cases were
euthyroid. 
In conclusion, as also proposed in the literature, we 
suggest that patients with T1D should be investigated 
annually for antibodies related to CD and ATD, regardless of
presence or absence of symptoms. The number of patients
in this study is inadequate to draw a conclusion on the 
association of HLA genotyping and autoimmune disorders;
however, it should be kept in mind that certain HLA groups
are prone to autoimmune disorders.
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